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doi:10.1016/j.ejvs.2009.05.012Abstract Objective: The role of TGF-b1 in venous ulcer healing and the signalling cascades
regulating dermal fibroblast function are poorly understood. To elucidate these processes,
we hypothesized that TGF-b1 facilitates wound healing by increasing chronic venous insuffi-
ciency (CVI) induced matrix contraction via intracellular cross-talk between TGF-b1 and the
ERK-1/2 MAP kinase signalling cascades.
Methods: Fibroblasts isolated from calf biopsies (LC) of patients with different severity of CVI
(CEAP, Clinical Etiological Anatomical Pathological classes) were seeded into 200 ml collagen
gels under isometric conditions. Fibroblasts from neonatal foreskins (HS68), non-CVI patients
(NC), and the ipsilateral normal thigh of each CVI patient (LT) served as controls. Thirteen
patients with CVI (class 2, nZ 5; class 4, nZ 5; class 6, nZ 3) and 2 non-CVI controls (NC,
nZ 2) were included in the study. All experimental conditions were determined by dosee
response and time-course experiments. Gels were cultured with/without 0.1 ng/ml TGF-b1
and with/without 50 mM PD98059 (MEK and downstream-MAPK inhibitor). Additional patient
fibroblasts were transfected with constitutively active Ras (pCMV-Ras) or an empty vector
(pCMV-b) with/without 0.1 ng/ml TGF-b1 and with/without 50 mm PD98059. The collagen gels
were released after 4 days and the percent contraction was determined by area measurements
using image analysis. Differences in a-smooth muscle actin (a-SMA) and ERK-1/2 MAPK (phos-
phorylated and total) protein levels were analyzed with western blotting.
Results: Gels seeded with CVI fibroblasts contracted more than HS68, NC and LT fibroblasts.
Inhibition of MAPK and/or stimulation with TGF-b1 increased the contraction of LC gels
compared to unstimulated controls. Agonist induced gel contraction correlated with CVI
disease severity. a-SMA protein expression in LC fibroblasts increased with MAPK inhibition
with/without TGF-b1 stimulation, and correlated with the degree of gel contraction. Transfec-
tion with pCMV-Ras (activator of ERK-1/2) inhibited gel contraction; this inhibition was nottreet, Suite 7600, Newark, NJ 07103, USA. Tel.: þ1 973 972 4599; fax: þ1 973 972 0092.
edu (P.J. Pappas).
td on behalf of European Society for Vascular Surgery.
Regulation of Matrix Contraction in CVI Patients 519reversed by addition of TGF-b1. Transfection with the pCMV-b empty vector had no effect on
gel contraction.
Conclusions: TGF-b1 stimulation of CVI patient fibroblasts grown in 3D collagen gels results in
conversion to a contractile phenotype through upregulation of a-SMA, and in enhanced gel
contraction. Inhibition of MAPK further increases gel contraction, while Ras activation of
ERK-1/2 inhibits TGF-b1-induced gel contraction. These responses correlate with increasing
CEAP severity. CVI fibroblast mediated gel contraction is therefore regulated through cross-
talk between the ERK-1/2 MAPK and TGF-b1 signalling cascades. These data identify poten-
tially clinically relevant therapeutic molecular targets that could enhance matrix contraction
and thereby improve venous ulcer wound healing.
Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Introduction
CVI and venous ulcer formation are the sequelae of chronic
ambulatory venous hypertension. Venous hypertension
causes extravasation of red blood cells (RBCs) and macro-
molecules that leads to inflammatory activation of the
venous microcirculation and leukocyte recruitment. In our
previous publications, we have demonstrated that CVI
dermal fibroblasts are an important target for leukocyte-
derived TGF-b1 and that CVI disease progression is associ-
ated with increased tissue levels of TGF-b1, MMP-2 activity,
and decreased TGF-b1-induced mitogenic responses of
fibroblasts.1e4 Although we have described how TGF-b1
regulates the development of CVI induced dermal fibrosis
and tissue remodelling, we have not identified the mech-
anisms that regulate venous ulcer formation or healing.
Wound formation and healing is dependent upon contrac-
tile interactions between fibroblasts and their surrounding
extracellular matrix. TGF-b1 influences these processes by
regulating the differentiation of fibroblasts into contractile
myofibroblasts and stimulating the synthesis of other
contractile proteins. This process is tightly regulated by the
ERK (Extracellular Regulated Kinase) MAP Kinase signalling
cascade (ERK-1/2, p42/44).5e8 We therefore hypothesized
that venous ulcer healing and formation would be regulated
by the effects TGF-b1 and the MAP Kinases have on fibro-
blast mediated matrix contraction.9 To test this hypothesis
we utilized three dimensional collagen gels seeded with CVI
dermal fibroblasts, in order to simulate the environmental
conditions observed in the lower extremities of CVI
patients.Materials and methods
Patient selection and CVI severity classification
Thirteen patients with different CVI severity (CEAP Class 2
e visible varicose veins, Class 4 e varicose veins and skin
hyperpigmentation, Class 6 e active skin ulceration) were
included in this study: class 2 (nZ 5), class 4 (nZ 5), class
6 (nZ 3). All patients underwent venous duplex ultrasound
scanning (Quantrum 2000; Siemens, Seattle, WA) to confirm
the presence of venous reflux. Six millimeter punch biopsies
were obtained from the affected lower calf (LC) and
compared to controls. Two subjects without CVI were
included to serve as non-CVI normal controls (NC).Ipsilateral thigh biopsies (LT) of normal skin from CVI
patients and neonatal foreskin fibroblasts (HS68) were used
as additional normal controls. Informed consent was
obtained from each participant. The study was approved by
the IRB of the New Jersey Medical School.Skin biopsy, fibroblast isolation from dermal
explants and western blotting
Skin biopsies, fibroblast isolation from biopsy samples and
western blotting were performed as previously descri-
bed.1e4,10e12 Bands were detected using an ECL-plus
western blotting detection kit on ECL Hyper-film (Amer-
sham, Piscataway, NJ). Band intensities were analyzed
with IS100 Digital Imaging. Blots were normalized by
comparing the ratios of samples to internal controls. All
experiments were performed in triplicate on passage 3 or
less cells.
Gel contraction assay
As described by Vaugham et al., we utilized in vitro,
isometric, three dimensional fibroblast-populated collagen
gel assays to test our hypothesis. These gels closely mimic
the environmental conditions observed in the dermis of CVI
patients.11,13 We first used a commercially available
neonatal foreskin fibroblast cell line (HS68; American Tissue
Type Culture Collection, Manassas, VA) to standardize the
isometric contraction assay. Subconfluent fibroblasts were
trypsinized, harvested, and 105 cells were seeded into
200 ml collagen solution. The solution comprised of 1.5%
Type I collagen (Upstate Biotech, New York, NY), 10% FBS,
3.5 mN NaOH with phenol red free 2 DMEM (DMEM powder
26.72 g/l, sodium bicarbonate 7.4 g/l, sodium pyruvate
100 mg/l). The fibroblastecollagen solution was placed on
pre-scored 6-well plates and allowed to polymerize, first at
room temperature for 15 min and then, with 5% CO2 at 37
C
for 45 min. After solidification, 3 ml of media (1 phenol
red free DMEM, 10% FBS, 1% PSN, 50 mg/ml ascorbic acid)
was added per well, and incubated at 37 C with 5% CO2 for
4 days to allow for isometric tension to develop. Media was
refreshed on day 2. Fibroblast type and reagents were
varied according to the experiments described below. Gels
were imaged on day 4 and re-imaged at timed intervals
after release with an IS100 Digital Imaging System (Alpha
Innotech Corp., San Leandro, CA). Gel images were digitally
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Figure 1 Patient fibroblast response to TGF-b1 stimulation. Gels were seeded with fibroblasts derived from the thighs of normal
controls (NC) and CVI classes 2, 4 and 6 (LT2-6), and from the calves of CVI classes 2, 4 and 6 (LC2-6). After stimulation with 0.1 ng/ml
of TGF-b1, gels were released and percent contraction was compared with untreated controls for each CVI class respectively
(a, p< 0.001; b, p< 0.001; c, p< 0.01; d, p< 0.001; e, p< 0.001, f, p< 0.001; g, p< 0.01).
520 P.J. Pappas et al.outlined (Image-Pro Plus, Media Cybernetics, Silver Spring,
MD) and the degree of contraction quantified as the percent
change in area after release (original area final area/
original area).
Matrix contraction by fibroblasts
In order to determine whether TGF-b1 promotes matrix gel
contraction by fibroblasts, and to determine the time
course of this response, collagen gels seeded with HS68
cells were incubated with TGF-b1 (0, 0.1 and 1.0 ng/ml;
Sigma, St. Louis, MO). On day 4, contraction was measured
at 10 and 60 min after release and compared to the pre-
release area. Thereafter, fibroblasts from CVI patients
(class 2, nZ 5; class 4, nZ 5; and class 6, nZ 3), internal
controls (LT, nZ 13), non-CVI controls (NC, nZ 2) and
controls (HS68) underwent gel contraction assays with/
without 0.1 ng/ml TGF-b1. In separate experiments, gels
seeded with fibroblasts were incubated with/without TGF-
b1 and with/without PD98059 (0, 50 or 100 mM; MEK and
downstream-MAPK inhibitor; Biomol, Plymouth Meeting,
PA). Contraction by fibroblasts from the calves (LC) of class
2, 4 and 6 CVI patients was compared to several controls
(LT, and NC). Furthermore, individual classes of CVI fibro-
blasts were also compared to each other to determine the
relationship between CVI severity and matrix contraction.
ERK and a-SMA expression in fibroblast gel
preparations
Collagen gels seeded with patient fibroblasts were incu-
bated with/without TGF-b1 and/or PD98059. Fibroblasts
were harvested at pre-release, 10, 60 and 120 min after
release as above, and the extracted protein was immu-
noassayed to determine the time course of ERK-1/2
expression. Thereafter, CVI patient fibroblast gels weresimilarly analyzed for expression levels of total/activated
ERK-1/2 and a-SMA.
RAS transfection of CVI patient fibroblasts
and gel contraction
RAS is a known upstream activator of ERK. We therefore
utilized RAS transfection to test the effect of ERK activa-
tion on fibroblast gel contraction. Plasmid vectors con-
taining a constitutively active mutant of H-RAS (pCMV-RAS)
or b-galactosidase (pCMV-b; both by BD Biosciences Clon-
tech, Palo Alto, CA) were transfected into fibroblasts. The
TransIT-LT1 polyamine transfection reagent (MIRUS-Fischer
Scientific, Pittsburgh, PA) was used according to the
manufacturer’s protocol. Briefly, TransIT-LT1 was diluted
in serum-free OptiMEM (Invitrogen, Carlsbad, CA) and
incubated at room temperature for 20 min. The plasmid
vector was added, and the mixture was incubated an
additional 20 min to allow the DNA and amphipathic poly-
amines to form complexes. Then, subconfluent fibroblasts
were transfected with a mixture of DMEM with 10% FBS,
Transit-LT1 (10 ml/ml) and 1.5 mg/ml DNA for 48 h at 37 C.
After the transfection, cells were selected in medium
containing neomysin (Life Technologies, Rockville, MD) for
7 days, and subcultured in 10% FBS containing DMEM. The
transfection efficacy of this protocol was tested in fibro-
blasts isolated from the calf (LC) and thigh (LT) of a class 4
CVI patient using pCMV-b and X-gal staining. Furthermore,
successful over-expression of Ras in cell lysates from
pCMV-Ras transduced fibroblasts was tested by Western
blotting as further evidence of transfection efficacy.
Thereafter, CVI patient (LC), LT, and NC fibroblasts were
transfected with pCMV-Ras. Transfected cells were seeded
in collagen gels as described and incubated with/without
1.0 ng/ml TGF-b1 for 4 days, followed by contraction
measurements.
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Figure 2 Contraction-response of fibroblast-seeded collagen gels to MEK inhibition. (a) Doseeresponse to MEK inhibition
(PD98059). Gels seeded with neonatal fibroblasts (HS68) were treated with increasing concentrations of PD98059 and percent
contraction for each group was compared to the untreated control (a, p< 0.001; b, p< 0.01). Responses were not different
between 50 and 100 mM concentrations. Contraction was further enhanced when 0.01 ng/ml TGF-b1 was added to PD98059 50 mM
(c, p< 0.001 vs. 50 mM PD alone) or to 100 mM (d, p< 0.05 vs. 100 mM PD98059 alone and p< 0.05 vs. combined TGF-b1þ 50 mM PD
98059). (b) Patient fibroblast response to MEK inhibition (PD98059). Gels were seeded with fibroblasts derived from the thighs of
normal controls (NC) and CVI classes 2, 4 and 6 (LT2-6), and from the calves of CVI classes 2, 4 and 6 (LC2-6). Gels were treated with
PD98059 and/or TGF-b1, and percent contraction for each group was measured. Gels treated with PD98059 alone did not
demonstrate increased contraction. Gels treated with TGF-b1 alone or in combination with PD98059 demonstrated increased
contraction compared to their respective untreated controls, that varied with the severity of disease (a, p< 0.001; b, p< 0.001; d,
p< 0.01; e, p< 0.001; g, p< 0.001; i, p< 0.001; j, p< 0.001). Combined treatment with TGF-b1þ PD98059 resulted in more
contraction than TGF-b1 alone in normal controls, class 2 and in class 4 patients (c, p< 0.05; f, p< 0.001; h, p< 0.05).
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All experiments were performed with 6 gels/patient and
repeated 3 times. Results are expressed as mean and
standard deviation (SD). Statistical significance was evalu-
ated using unpaired t-tests for comparing two means, and
by ANOVA with Tukey’s post-hoc test for multiple compar-
isons. Data were analyzed with Prism GraphPad Instat
(GraphPad Software, San Diego, CA), and p< 0.05 was
considered statistically significant.Results
TGF-b1 induces matrix contraction by
CVI patient fibroblasts
TGF-b1-induced HS68 fibroblast gel contraction in a dose
dependent fashion with maximal contraction being ach-
ieved at 0.1 ng/ml, 60 min after release (p< 0.01 vs.
control; data not shown). We therefore selected TGF-b1
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Figure 3 ERK-1/2 phosphorylation in response to release of fibroblast-seeded collagen gels. (a) Time course of ERK-1/2 response
to gel release. Representative western blot and graph demonstrating relative band intensities of protein expression for total and
phosphorylated (pERK-1/2) ERK-1/2 after the release of gels seeded with HS68 fibroblasts (a, p< 0.001). Total ERK-1/2 expression
remained unchanged. (b) pERK-1/2 response to TGF-b1 stimulation and MEK blockade (PD98059). Representative western blots and
graphs demonstrating relative band intensities of protein expression for pERK-1/2 10 min after the release of gels seeded with
fibroblasts derived from calves (LC) and thighs (LT) of classes 2, 4 and 6 CVI patients. Gels were stimulated with 0.01 ng/ml TGF-b1
prior to release. Percent contraction of LC gels (first graph) compared to the respective untreated controls in each group (a,
p< 0.001; b, p< 0.05; c, p< 0.001; d, p< 0.001; e, p< 0.01; f, p< 0.05). Expression could not be restored with simultaneous
stimulation with TGF-b1 (for each, compared to their respective controls). Percent contraction of LT gels (second graph). A similar
response was observed when gels seeded with fibroblasts from CVI patient thighs (LT) were tested with TGF-b1 (a, p< 0.01; b,
p< 0.05; c, p< 0.01; d, p< 0.05; e, p< 0.001; f, p< 0.05). (c) Total ERK-1/2 response to TGF-b1 stimulation and MEK blockade
(PD98059). Representative western blots and graphs demonstrating that no change in total ERK-1/2 expression were observed when
gels seeded with CVI patient fibroblasts were treated with TGF-b1, PD98059, or a combination of TGF-b1þ PD98059.
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Figure 3 (continued).
Regulation of Matrix Contraction in CVI Patients 5230.1 ng/ml and 60 min as the optimal agonist dose and
post-release measurement time respectively, for future
experiments. Of note, we harvested and counted fibro-
blasts in collagen gels after 4 days to ensure that matrix
contraction results were not due to TGF-b1 or three
dimensional collagen gel stimulation of fibroblast prolifer-
ation. The analysis did not demonstrate an increase in
fibroblasts higher than the number of cells seeded on day 1
(data not shown). Therefore, our observations of increased
collagen gel contraction were likely secondary to altered
phenotype, and not increased cell number.
Based on these observations, we tested the effect of
TGF-b1 on the contraction of gels seeded with fibroblasts
derived from two non-CVI patients and thirteen patients
with different CVI severities (CEAP class 2 (nZ 5), class 4
(nZ 5), class 6 (nZ 3)). Ipsilateral thigh biopsies (LT) from
normal appearing skin were used as additional internal
controls. TGF-b1 at 0.1 ng/ml enhanced collagen gel
contraction of normal controls (NC, p< 0.001), class 2 CVI
(LC2, p< 0.01), class 4 (LC4, p< 0.001), and class 6 (LC6,
p< 0.01), CVI patient fibroblasts compared to non-CVI
derived fibroblasts and fibroblasts obtained from ipsilateral
normal thigh biopsies (LT cells) (Fig. 1). A progressiveincrease in fibroblast mediated gel contraction by TGF-b1
correlated with CVI disease severity (class 4 versus class 2
cells (LC4 vs. LC2, p< 0.001), class 6 versus class 2 cells
(LC6 vs. LC2, p< 0.001), and class 6 versus class 4 fibro-
blasts (LC6 vs. LC4, p< 0.05, Fig. 1). Therefore, a graded
response to TGF-b1 was observed according to increasing
CVI disease severity.
Of note, untreated gels seeded with calf fibroblasts
also demonstrated progressively increasing contraction
with CVI severity (p< 0.05 for both, LC2 vs. LC4, and LC4
vs. LC6). This was not seen when the responses of
untreated thigh fibroblasts were compared (pZ not
significant for LT2 vs. LT4 and LT4 vs. LT6). Stimulation
with TGF-b1 resulted in a further increase of gel
contraction above that observed with unstimulated gels.
Interestingly, TGF-b1-treated thigh cells of class 6 patients
contracted more than those of class 2 patients (LT2 vs.
LT6, p< 0.01) indicating that molecular defects in patient
fibroblasts extended well beyond the clinically affected
part of the lower extremity. These data may reflect
effects related to pressure as LC fibroblasts are exposed to
higher levels of venous hypertension compared to LT
fibroblasts in vivo.
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Figure 4 (continued)
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contraction by CVI patient fibroblasts
Inhibition of MAPK with 50 (p< 0.01) and 100 (p< 0.01) mM
PD98059 enhanced gel contraction caused by HS68 fibro-
blasts, compared to untreated cells (Fig. 2a). When gels
containing HS68 cells were simultaneously incubated with
0.1 ng/ml of TGF-b1 and 50 (p< 0.001) or 100 (p< 0.05) mM
PD98059, an even greater contraction was observed
compared to PD98059 alone (Fig. 2a).
Based on these observations, we tested the effect of
MAPK inhibition on gels constructed with CVI patient
fibroblasts. In normal control (NC) patients, PD98059 alone
did not alter contraction, although gel contraction was
enhanced in the presence of TGF-b1 alone (p< 0.001), and
in conjunction with 50 mM PD98059 (p< 0.001) when
compared to no treatment (Fig. 2b). When compared with
untreated class 2 patient fibroblasts, treatment with TGF-
b1 (p< 0.01), and combined TGF-b1þ PD98059 (p< 0.001)
enhanced gel contraction. Combined treatment resulted in
more contraction than TGF-b1 alone (p< 0.001). Similarly,Figure 4 Contraction of gels seeded with Ras-transfected CVI pat
of Ras and activates ERK-1/2. (Top panel) Fibroblasts derived fro
chronic venous insufficiency were transfected with an active m
expression was compared to controls by western blotting. (Lower p
patient underwent similar transfections and pERK-1/2 expression
transfection reduces TGF-b1-induced matrix contraction in class 2
class 2 CVI patients were transfected with (pCMV-Ras) or empty vec
b1. Percent contraction for each group was compared with the resp
p< 0.001; c, p< 0.05; d, p< 0.05; e, p< 0.001). (c) ERK-1/2 ac
contraction in class 4 CVI. Gel contraction after similar transfection
patients that underwent similar treatment (a, p< 0.01; b, p< 0.0
vation by Ras transfection reduces TGF-b1-induced matrix contract
fibroblasts from the calves (LC) and thighs (LT) of class 6 CVI patien
c, p< 0.01; d, p< 0.01).class 4 fibroblasts treated with TGF-b1 (p< 0.001), and
combined TGF-b1þ PD98059 (p< 0.001) had increased
contraction, while the response was maximal in the pres-
ence of the combination compared to TGF-b1 alone
(p< 0.05, Fig. 2b). While contraction was also increased by
TGF-b1 (p< 0.001) or its combination with PD98059
(p< 0.001) in class 6 patients, the responses were not
different from each other. Therefore, a graded response to
MAPK inhibition was observed according to increasing CVI
disease severity.
Matrix contraction by CVI patient fibroblasts is
associated with increased pERK-1/2 expression
Western blotting for the phosphorylated form of ERK-1/2
demonstrated increased protein activation in unstimulated
HS68 cells 10 min after gel release (p< 0.001). Phosphory-
lation returned to the pre-release baseline by 60 min
(Fig. 3a). The expression of total ERK-1/2 remained unal-
tered (Fig. 3a gel image). The response by patient fibro-
blasts followed a similar time course (data not shown).ient fibroblasts. (a) Transfection with Ras enhances expression
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Figure 5 Expression of a-SMA in CVI patient fibroblasts in response to TGF-b1 stimulation and MAPK inhibition. (a) Representative
western blots for a-SMA expression in fibroblasts from class 2, 4 and 6 CVI patients. Cells were seeded in collagen gels, treated with
TGF-b1 and/or PD98059, and protein measured prior to release. (b) Graphs demonstrating relative band intensities of protein
expression for a-SMA before release of gels seeded with fibroblasts derived from calves (LC) and thighs (LT) of classes 2 CVI
patients. Gels were treated with 0.01 ng/ml TGF-b1 and/or 50 mM PD98059 (a, p< 0.01; b, p< 0.001 vs. untreated cells). (c) Graph
demonstrating results of similar experiments with fibroblasts derived from classes 4 CVI (a, p< 0.05; b, p< 0.01; c, p< 0.001 vs.
untreated cells). (d) Graph demonstrating results of similar experiments with fibroblasts derived from classes 6 CVI (a, p< 0.05; b,
p< 0.01; c, p< 0.05; d, p< 0.001 vs. untreated cells).
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Regulation of Matrix Contraction in CVI Patients 527In subsequent experiments, we tested ERK activation,
10 min post-release, after subjecting gels seeded with
patient fibroblasts to various agents. When fibroblasts
derived from patient calves (LC) were exposed to PD98059
alone, or in conjunction with TGF-b1, activated ERK-1/2
was significantly reduced across all CVI classes (Fig. 3b).
Despite being derived from visibly unaffected skin, fibro-
blasts from patient thighs also demonstrated a similarly
reduced activation of ERK-1/2 in the presence of PD98059
alone, or in conjunction with TGF-b1 (Fig. 3b). The
expression of total ERK-1/2 remained unchanged in both LC
and LT fibroblasts across all CVI classes (Fig. 3c).
H-RAS transfection inhibits TGFb1-induced matrix
contraction by CVI patient fibroblasts
We confirmed that we were able to achieve a transfection
efficacy of 56% with pCMV-b as tested with X-gal staining
(data not shown) in fibroblasts derived from the calf (LC)
and thigh (LT) of a class 4 CVI patient. Furthermore,
pCMV-H-RAS-transfected CVI fibroblasts demonstrated
enhanced Ras expression in cell lysates by western blot-
ting (Fig. 4a). Because RAS is a known upstream activator
of ERK, we used it to test the significance of ERK acti-
vation on fibroblast gel contraction. Primary cultures of
fibroblasts from normal subjects (NC) and patients with
class 2, 4 and 6 CVI were transiently transfected with
empty vector (pCMV-b) or an active mutant of Ras (pCMV-
H-Ras). Cells transfected with pCMV-H-RAS demonstrated
a significant reduction in matrix contraction across class
2, 4, and 6 patients, which remained attenuated even
when they were stimulated with TGF-b1 (Fig. 4b, c and
d). Contraction was unaltered by transfection with
pCMV-b.Conversion to contractile phenotype with a-SMA
expression is enhanced with TGF-b1 stimulation
and/or MAPK inhibition
Expression of a-SMA was increased in HS68 cells grown in
collagen gels in the presence of 50 mM PD98059 alone or
0.1 ng/ml TGF-b1 alone. The response was maximal when
gels were stimulated with a combination of PD98059 and
TGF-b1. This indicated that MAP kinases regulate TGF-
b1-induced intracellular contractile proteins and the
development of a myofibroblast phenotype.
Based on these observations, we tested a-SMA expres-
sion in CVI fibroblasts to examine the regulation of myofi-
broblast phenotype according to CVI disease severity. In
class 2 fibroblasts, a-SMA expression was increased in the
diseased (LC) fibroblasts in response to MAPK inhibition
(p< 0.001), TGF-b1 stimulation (p< 0.01), and a combina-
tion of both (p< 0.001) when compared to LT and to
unstimulated LC cells (Fig. 5a and b). In class 4 (Fig. 5a and
c) and class 6 (Fig. 5a and c) CVI fibroblasts, MAPK inhibition
with or without TGF-b1 stimulation increased a-SMA
expression. This observation suggests that with CVI disease
progression, TGF-b1 does not affect a-SMA formation and
that other mechanisms are involved in the transformation
of fibroblasts to myofibroblasts.Discussion
TGF-b1 mediates tissue remodelling through regulation of
collagen synthesis and degradation, matrix metal-
loproteinase (MMP) synthesis, and differentiation of fibro-
blasts into contractile myofibroblasts.2,4 We have
previously reported modest changes in MMP composition
and decreased fibroblast proliferative responses in patients
with CVI.14 Based on our previous publications, it appears
unlikely that dysregulation of MMP synthesis or inhibition of
fibroblast proliferation, plays a major role in venous ulcer
formation or healing. We therefore hypothesized that
decreased fibroblast mediated matrix contraction was the
underlying cause for poor venous ulcer healing. Fibroblast
mediated matrix contraction, in association with keratino-
cyte epithelialization is the primary method for normal
wound healing. Our current data indicate that CVI fibro-
blasts placed in three dimensional collagen matrices,
exhibit progressive increases in matrix remodelling and
contraction that correlates with disease severity and the
presence of TGF-b1 (Fig. 2b). TGF-b1-induced contraction
was further enhanced when MAPK signalling was blocked.
MAPK blockade was also associated with a corresponding
increase in a-SMA expression. Conversely, contraction was
reduced when ERK-1/2 was up-regulated, thereby providing
evidence that ERK-1/2 modulates TGF-b1-induced matrix
contraction. The observation that the ERK MAP Kinases
regulate matrix contraction indicates that these proteins
may be molecular targets for drug development aimed at
increasing wound contraction.
Importantly, we found that the cross-talk between ERK-
1/2 and TGF-b1 was altered according to CVI disease
severity. Contrary to our hypothesis, our data indicate that
CVI disease progression is associated with increased fibro-
blast mediated contractile properties and a potential ability
to accelerate venous ulcer healing. A consequence of this
adaptive wound healing response is increased stored kinetic
energy and tension in the dermis of CVI patients. We
observed gel contraction in unstimulated gels indicating that
fibroblasts surrounded by an ECM, exert a baseline degree of
tension on their surrounding environment. This tension is
increased when stimulated with TGF-b1 and/or ERK inhibi-
tion. Injury to the CVI dermal architecture releases stored
kinetic energy in the dermis and clinically manifests itself
initially as wound separation. This clinical situation is anal-
ogous to a stretched rubber band. When external forces are
used to stretch a rubber band, tension is exerted on the
elastic fibers within the band. When the rubber band is
released, the stored kinetic energywithin the elastic fibers is
released and the band contracts. It is clear that increased
fibroblast contractility is beneficial in healing wounds.
However, in patients with dermal fibrosis and increased
matrix tension, an injury that causes architectural damage
may be the underlying stimulus that releases kinetic energy
and causes initial wound separation.
Why do venous ulcers heal poorly if CVI dermal fibro-
blasts demonstrate increased matrix contraction?
Numerous other factors such as bacterial contamination
and persistent venous hypertension play a role in poor
venous ulcer healing. We believe that venous hypertension
affects ulcer wound healing via mechanotransduction of
528 P.J. Pappas et al.pressure to CVI dermal fibroblasts. It is our contention that
pressure activates cellular senescence processes and stim-
ulates signalling cascades that inhibit TGF-b1 regulated
matrix contraction, resulting in prolonged wound healing.
Similar to other investigators, we have reported a loss of
growth factor responsiveness in fibroblasts isolated from
venous ulcer patients indicating that cellular senescence
may be involved in CVI dermal pathology.15 Although sen-
escent fibroblasts lose their proliferative capacity, they
remain synthetically active. The increased synthesis and
secretion of proteins by senescent fibroblasts cause an
alteration in the tissue microenvironment that can affect
tissue structure and function.15 Our current data strongly
suggest a link between TGF-b1 signalling and CVI fibroblast
senescense. We believe this link may be RAS mediated.
Campisi et al. have reported that over-expression of
Oncogenic RAS stimulates ERK MAP Kinase signalling and the
induction of a senescence response in other fibroblast
strains.15 RAS signalling, may therefore affect CVI ulcer
healing.
There is a large body of evidence that implicates
integrins as ‘‘mechanosensors’’ and ‘‘mechanotransducers’’
of externally applied forces. Integrins are heterodimeric
transmembrane cell surface receptors that attach the
extracellular matrix (ECM) to the intracellular actin cytos-
keleton.16e19 Reports indicate that forces exerted on the
ECM are converted into chemical signals through interac-
tions with integrin receptors in bone remodelling by oste-
ocytes, cardiac hypertrophy by myocytes, vascular smooth
muscle cells during constriction of blood vessels and
maintenance of skin tone by dermal fibroblasts.13,20e22 The
contraction of ECM by dermal fibroblasts isolated from
scleroderma and hypertrophic scar patients is regulated by
integrins that sense and transduce signals to the actin
cytoskeleton via the formation of focal adhesion contacts
(FAs).11,13,21 In these situations, TGF-b1 increases matrix
contraction, which is also associated with increased
synthesis of a-SMA and the development of a contractile
phenotype. Similarly, our data demonstrate that CVI
disease progression is associated with TGF-b1 directed
differentiation of fibroblasts into myofibroblasts and the
induction of a-SMA contractile proteins (Fig. 5). The
development of a contractile phenotype increases
mechanical stress in the matrix as evidenced by enhanced
contraction of fibroblast gels according to CVI disease
severity (Fig. 1). These data suggest that venous hyper-
tension may affect venous ulcer healing through stimula-
tion of fibroblast mechanotransducers. Future experiments
should investigate whether pressure applied to CVI dermal
fibroblasts in three dimensional collagen matrices will
transmit force through integrin activation of intracellular
ligands such as RAS.Conclusions
Fibroblasts grown in 3D collagen gels are useful models to
study cellular responses in CVI. TGF-b1 stimulation of CVI
patient fibroblasts grown in collagen gels results in differ-
entiation of fibroblasts to a contractile phenotype through
increased expression of a-SMA. This conversion is associ-
ated with enhanced matrix contraction that correlates withincreasing CEAP disease severity. Simultaneous inhibition of
MAPK further increases contraction, while RAS activation of
ERK-1/2 inhibits TGF-b1-induced matrix contraction. These
responses also correlate with disease severity and suggest
an adaptive response to chronic venous hypertension
exposure. Increased fibroblast mediated matrix contraction
is a positive attribute when trying to heal an ulcer.
However, an unintended consequence of this adaptive
response is increased tension in the dermis of CVI patients.
An injury that causes loss of dermal architecture releases
the kinetic energy stored in the matrix resulting initially in
wound separation. Based on our data, we speculate that
persistent venous hypertension may stimulate RAS produc-
tion via pressure mediated mechanotransduction. RAS
stimulation of the ERK MAP Kinases would inhibit TGF-b1
mediated matrix contraction providing a possible cause for
poor venous ulcer healing. In addition to improving our
understanding of the molecular mechanisms underlying CVI
induced dermal changes, these findings provide additional
molecular targets that could be modulated to inhibit the
development or progression of dermal sequelae associated
with CVI.Acknowledgements
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